The University of Chicago Header Logo

Connection

Mary Rinella to Fatty Liver

Back to Details
This is a "connection" page, showing publications Mary Rinella has written about Fatty Liver.
Mary Rinella
Connection Strength
8.819
Fatty Liver
  1. Variance Between Clinical Guidance and Real-World Management of Metabolic Dysfunction-associated Steatotic Liver Disease in the United States. Clin Gastroenterol Hepatol. 2025 Feb; 23(2):374-376.e3.
    View in: PubMed
    Score: 0.802
  2. Steatotic liver disease: a new name to reflect the combined role of alcohol and metabolic dysfunction. Nat Med. 2024 Apr; 30(4):933-936.
    View in: PubMed
    Score: 0.780
  3. Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition": EASL, AASLD and ALEH stand united to advance the field of steatotic liver disease. J Hepatol. 2024 07; 81(1):e20-e21.
    View in: PubMed
    Score: 0.765
  4. Defining an approach for therapeutic strategies in metabolic dysfunction-associated steatotic liver disease after liver transplantation. Hepatology. 2025 Sep 01; 82(3):766-776.
    View in: PubMed
    Score: 0.764
  5. Authors' response. J Acad Nutr Diet. 2013 Feb; 113(2):211-2.
    View in: PubMed
    Score: 0.360
  6. Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology. 2012 Nov; 56(5):1741-50.
    View in: PubMed
    Score: 0.354
  7. A myriad of pathways to NASH. Clin Liver Dis. 2012 Aug; 16(3):525-48.
    View in: PubMed
    Score: 0.345
  8. The role of diet and nutrient composition in nonalcoholic Fatty liver disease. J Acad Nutr Diet. 2012 Mar; 112(3):401-9.
    View in: PubMed
    Score: 0.338
  9. Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease? Hepatology. 2011 Oct; 54(4):1118-20.
    View in: PubMed
    Score: 0.328
  10. Dysregulation of the unfolded protein response in db/db mice with diet-induced steatohepatitis. Hepatology. 2011 Nov; 54(5):1600-9.
    View in: PubMed
    Score: 0.324
  11. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol. 2011 Jul-Sep; 10(3):277-86.
    View in: PubMed
    Score: 0.322
  12. Non-alcoholic fatty liver disease: is bariatric surgery the answer? Clin Liver Dis. 2009 Nov; 13(4):689-710.
    View in: PubMed
    Score: 0.287
  13. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res. 2008 May; 49(5):1068-76.
    View in: PubMed
    Score: 0.254
  14. Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2025 Nov; 10(11):998-1012.
    View in: PubMed
    Score: 0.216
  15. Phosphatidylethanol in steatotic liver disease. J Hepatol. 2025 Nov; 83(5):1189-1203.
    View in: PubMed
    Score: 0.214
  16. Call to action-Pediatric MASLD requires immediate attention to curb health crisis. Hepatology. 2025 Nov 01; 82(5):1341-1351.
    View in: PubMed
    Score: 0.212
  17. Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis. J Gastroenterol. 2025 Jul; 60(7):891-904.
    View in: PubMed
    Score: 0.208
  18. Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers. 2025 Mar 06; 11(1):14.
    View in: PubMed
    Score: 0.208
  19. Risk Stratification for Chronic Kidney Disease After Liver Transplant for Metabolic Dysfunction-associated Steatohepatitis (MASH) Cirrhosis: Results From the NailMASH Consortium. Transplantation. 2025 03 01; 109(3):484-495.
    View in: PubMed
    Score: 0.203
  20. Validating the new nomenclature of steatotic liver disease in patients with excessive alcohol intake - Authors' reply. Lancet Gastroenterol Hepatol. 2024 05; 9(5):409-410.
    View in: PubMed
    Score: 0.196
  21. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol Hepatol. 2024 03; 9(3):218-228.
    View in: PubMed
    Score: 0.192
  22. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol. 2004 Jan; 40(1):47-51.
    View in: PubMed
    Score: 0.192
  23. Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition'. Ann Hepatol. 2024 Jul-Aug; 29(4):101178.
    View in: PubMed
    Score: 0.191
  24. Steatotic liver disease, a useful construct in primary care that doesn't upset the apple cart. Hepatology. 2024 06 01; 79(6):1252-1254.
    View in: PubMed
    Score: 0.191
  25. Dual-echo, chemical shift gradient-echo magnetic resonance imaging to quantify hepatic steatosis: Implications for living liver donation. Liver Transpl. 2003 Aug; 9(8):851-6.
    View in: PubMed
    Score: 0.186
  26. Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transpl. 2001 May; 7(5):409-14.
    View in: PubMed
    Score: 0.159
  27. Editorial: Age and Non-Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock? Am J Gastroenterol. 2017 05; 112(5):752-754.
    View in: PubMed
    Score: 0.121
  28. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015 Jun 09; 313(22):2263-73.
    View in: PubMed
    Score: 0.106
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.